(ALPN) |
| 0 (0%) 10-10 16:16 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 75.92 |
| Resistance 1: | 65.00 |
| Pivot price: | 64.79 |
| Support 1: | 64.63 |
| Support 2: | 64.40 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.640 |
| Book Value | 5.070 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | -65.17 |
| Operating Margin (%) | -322.75 |
| Return on Assets (ttm) | -10.1 |
| Return on Equity (ttm) | -14.7 |
Company news
Thu, 15 May 2025
Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice - Frontiers
Mon, 27 May 2024
Atomic Legacy Preservation Network - Department of Energy (.gov)
Fri, 10 May 2024
Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ... - Yahoo Finance
Wed, 10 Apr 2024
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences - Stock Titan
Tue, 06 Jun 2023
Examining HTTP/3 usage one year on - The Cloudflare Blog
Fri, 17 Mar 2023
Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial - ScienceDirect.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
